Indivior (INDV) Competitors

Verona Pharma (NASDAQ:VRNA) and Indivior (NASDAQ:INDV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability.

Does the MarketBeat Community believe in VRNA or INDV?

Verona Pharma received 319 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 80.84% of users gave Verona Pharma an outperform vote.

Company	Underperform	Outperform
Verona Pharma	Outperform Votes 329 80.84%	Underperform Votes 78 19.16%
Indivior	Outperform Votes 10 100.00%	Underperform Votes No Votes

Do analysts recommend VRNA or INDV?

Verona Pharma currently has a consensus target price of $57.14, suggesting a potential downside of 15.92%. Indivior has a consensus target price of $16.00, suggesting a potential upside of 89.01%. Given Indivior's stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
Indivior	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has more risk and volatility, VRNA or INDV?

Verona Pharma has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Indivior has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Does the media refer more to VRNA or INDV?

In the previous week, Indivior had 5 more articles in the media than Verona Pharma. MarketBeat recorded 11 mentions for Indivior and 6 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 0.76 beat Indivior's score of 0.25 indicating that Verona Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verona Pharma	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indivior	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do insiders and institutionals believe in VRNA or INDV?

85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is VRNA or INDV more profitable?

Verona Pharma has a net margin of 0.00% compared to Indivior's net margin of -0.17%. Verona Pharma's return on equity of -79.54% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-79.54%	-43.49%
Indivior	-0.17%	-351.08%	15.24%

Which has better earnings & valuation, VRNA or INDV?

Indivior has higher revenue and earnings than Verona Pharma. Indivior is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	$460K	11,810.27	-$54.37M	-$1.92	-35.40
Indivior	$1.09B	1.07	$2M	-$0.04	-211.57

Summary

Verona Pharma and Indivior tied by winning 9 of the 18 factors compared between the two stocks.